肿瘤相关巨噬细胞在肝癌组织中的表达及其与VEGF的相关性

目的：研究肿瘤相关巨噬细胞(TAMs)在肝癌中的表达及其与血管内皮生长因子（VEGF）的相关性。方法采用免疫组织化学双染方法检测2010年1月至2014年1月在我院行肝癌切除术后收集的肝癌组织标本95例，采用免疫组化法分别检测组织中CD163(TAMs标记物)及VEGF的表达，光镜下对TAMs计数及VEGF阳性表达进行分析，并分析其与临床病理参数之间的关系。结果在肝癌组织分期Ⅰ~Ⅱ期的肝癌组织中TAMs平均浸润(38.39±22.13)个，Ⅲ~Ⅳ期的肝癌组织中TAMs平均浸润(48.95±25.32)个(P<0.05)，未出现远处转移的肝癌患者组织中TAMs平均浸润(37.41±22.48)个，而出现远处转移的肝癌患者组织中TAMs平均浸润(47.56±26.45)个(P<0.05)。VEGF主要是在肿瘤细胞中呈中等强度表达；并且其表达强度与TAMs计数呈正相关关系(r=0.782，P<0.05)。结论 TAMs在肝癌组织中的表达与肝癌侵袭转移特性以及分期有密切关系，并与VEGF表达呈正相关关系，提示TAMs与VEGF的表达可用来预测肿瘤的恶性程度，以及作为肝癌的辅助治疗和改善预后的潜在靶点。

Expression of tumor-associated macrophage in the tissue of hepatocellular carcinoma and the correlation with vascular endothelial growth factor

Objective To investigate the expression of tumor-associated macrophages in hepatocellular carci-noma and its correlation with vascular endothelial growth factor (VEGF). Methods Ninety-five samples of hepatocel-lular carcinoma tissue collected from the patients undergoing hepatectomy from January 2010 to January 2014 in our hospital were detected by double immunohistochemical staining. The expression of CD163 (TAMs marker) and VEGF in hepatocellular carcinoma were detected by immunohistochemistry. Then TAMs count and the positive expression of VEGF were analyzed under light microscope, and their relationship with clinical pathological parameters were anal-zyed. Results The average infiltration of TAMs was (38.39 ± 22.13) in hepatocellular carcinoma of stageⅠ~Ⅱ, (48.95±25.32) in hepatocellular carcinoma of stageⅢ~Ⅳ(P<0.05), which was (37.41±22.48) in the patients without distant metastasis and (47.56 ± 26.45) in the patients with distant metastasis (P<0.05). VEGF was moderately ex-pressed in hepatocellular carcinoma, and the expression intensity was positively correlated with TAMs count (r=0.782, P<0.05). Conclusion The expression of TAMs in the hepatocellular carcinoma has close relationship with the invasion and metastasis of hepatocellular carcinoma as well as staging, and it is positively correlated with expres-sion of VEGF. The expression of TAMs and VEGF can be used to predict the malignant degree of tumor, and as an adju-vant therapy of liver cancer and potential targets to improve the prognosis.